0.8852

3.35% 0.0287

After Hours: .92 0.0348 +3.93%

Reviva Pharmaceuticals Holdings Inc (RVPH)

Overview News Price History Option Chain Financials Discussions Forecast

Reviva Pharmaceuticals Holdings Inc stock is traded at $0.8852, with a volume of 356.53K. It is up +3.35% in the last 24 hours and down -64.16% over the past month. Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.

Previous Close:

$0.8565

Open:

$0.89

24h Volume:

356.53K

Relative Volume:

0.73

Market Cap:

$11.34M

Revenue:

Net Income/Loss:

$-19.86M

P/E Ratio:

-0.1311

EPS:

-6.7506

Net Cash Flow:

$-24.59M

1W Performance:

+12.05%

1M Performance:

-64.16%

6M Performance:

-92.98%

1Y Performance:

-94.13%

1-Day Range:

$0.835

$0.90

1-Week Range:

$0.76

$0.92

52-Week Range:

$0.59

$23.20

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name

Reviva Pharmaceuticals Holdings Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(408) 501-8881

Address

10080 N WOLFE ROAD, CUPERTINO

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

RVPH's Discussions on Twitter

Compare RVPH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVPH Reviva Pharmaceuticals Holdings Inc	0.8852	10.97M	0	-19.86M	-24.59M	-6.7506
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Downgrade	D. Boral Capital	Buy → Hold
Sep-29-25	Initiated	Chardan Capital Markets	Buy
Sep-20-23	Initiated	ROTH MKM	Buy
Jun-08-23	Initiated	The Benchmark Company	Speculative Buy
Jan-24-22	Initiated	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News

Apr 15, 2026

Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 - Investing.com Australia

Apr 15, 2026

Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52 - MSN

Apr 15, 2026

Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart

Apr 15, 2026

Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine By Investing.com - Investing.com Australia

Apr 15, 2026

Reviva Updates Brilaroxazine Strategy and Funding Outlook - TipRanks

Apr 15, 2026

Reviva Announces patent filing, FDA alignment plans and RECOVER-2 timing - TradingView — Track All Markets

Apr 15, 2026

Reviva Announces Letter to Shareholders - The Manila Times

Apr 15, 2026

Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan

Apr 15, 2026

$23M on hand, patent push: Reviva lays out 2026 drug roadmap - Stock Titan

Apr 15, 2026

Apr 13, 2026

Aug Weekly: Is Reviva Pharmaceuticals Holdings Inc forming a bullish divergencePortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn

Apr 13, 2026

Growth Report: Can Reviva Pharmaceuticals Holdings Inc sustain earnings growthMarket Risk Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN

Apr 09, 2026

What date does Reviva Pharmaceuticals's (RVPH) report EarningsEarnings Calendar & Announcement - Zacks Investment Research

Apr 09, 2026

Maxim Group downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN

Apr 09, 2026

Apr 08, 2026

Short Squeeze: How do insiders feel about Reviva Pharmaceuticals Holdings Inc2026 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Investment Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart money2026 PreEarnings & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Energy Moves: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant impacted by rising rates2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn

Apr 06, 2026

Apr 05, 2026

Volume Summary: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant outperform during market rallies2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn

Apr 05, 2026

Aug Analyst Calls: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Form S-3Registration statement under Securities Act of 1933 - ADVFN

Apr 04, 2026

Apr 02, 2026